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Allogeneic Cardiospheres Safely Boost
Cardiac Function and Attenuate Adverse
Remodeling After Myocardial Infarction in
Immunologically Mismatched Rat Strains
Eleni Tseliou, MD,* Sara Pollan, MS,* Konstantinos Malliaras, MD,* John Terrovitis, MD,‡
Baiming Sun, MD,* Giselle Galang, BS,* Linda Marba´n, PHD,*† Daniel Luthringer, MD,*
Eduardo Marba´n, MD, PHD*†
Los Angeles, California; and Athens, Greece
Objectives We sought to characterize the immunologic profile of allogeneic cardiospheres, which are 3-dimensional, self-
assembling, cardiac-derived microtissues, and to evaluate their safety and efficacy in repairing ischemic heart
tissue.
Background Intramyocardial injection of autologous cardiospheres ameliorates remodeling and improves global function in
infarcted myocardium. It is as yet unknown whether allogeneic cardiospheres are similarly effective without elic-
iting deleterious immune reactions.
Methods We expanded cardiospheres from male Wistar Kyoto rat hearts and injected them surgically in the peri-infarct
zone of Wistar Kyoto (syngeneic group, n  28) and Brown Norway female rats (allogeneic group, n  29). Fe-
male rats from both strains (n  37) injected with normal saline served as controls.
Results In vitro, cardiospheres expressed a low immunogenic profile and inhibited proliferation of alloreactive T cells. In
vivo, cell engraftment was similar in the syngeneic and allogeneic groups 1 week and 3 weeks after transplanta-
tion. Reductions in scar size and scar collagen content and increases in viable mass in the risk region were ac-
companied by improvements in left ventricular function and attenuation of left ventricle remodeling that were
sustained during 6 months of follow up. Transplantation of allogeneic cardiospheres increased tissue expression
of the regenerative growth factors vascular endothelial growth factor, hepatocyte growth factor, and insulin-like
growth factor-1, stimulating angiogenesis. Syngeneic and allogeneic cardiospheres attenuated the inflammatory
response observed histologically in the peri-infarct region.
Conclusions Allogeneic cardiospheres increase viable myocardium, decrease scar, improve function, and attenuate adverse re-
modeling in the infarcted rat heart, without deleterious immunological sequelae. These observations lay the ground-
work for developing cardiospheres as a novel off-the-shelf microtissue product for myocardial regeneration. (J Am
Coll Cardiol 2013;61:1108–19) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.10.052n
t
(
nHeart-derived cell products appear to be particularly prom-
ising from a therapeutic perspective (1–5). Among these,
cardiosphere-derived cells (CDCs) have been found to
reduce scar while producing new functional heart tissue in
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(Cardiosphere-Derived Cells for Heart Regeneration After
Myocardial Infarction) trial (6). The CDCs, as their name
implies, are created from self-assembling heart-derived
multicellular clusters named “cardiospheres,” which are
unique in being preformed microtissues (7,8). Cardio-
spheres themselves are effective in tissue regeneration, but
their size (50 to 100 m diameter) complicates intracoro-
ary administration (8–11). Direct intramyocardial injec-
ion is a viable alternative for delivery of cardiospheres
12,13). Despite the greater ease (and safety) of intracoro-
ary delivery, intramyocardial administration merits further
xploration given compelling evidence that cardiospheres
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March 12, 2013:1108–19 Allogeneic Cardiospheres After Cardiac Infarctionmay surpass CDCs in terms of functional benefit and
regenerative potency (12–14). Thus, the disadvantages of in-
tramyocardial delivery may be offset by greater efficacy. Here, we
investigate the safety and efficacy of intramyocardial allogeneic
ardiosphere administration in a rat model of acute MI.
In the emerging field of cell therapy, it is generally
ssumed that transplanted cells will behave immunologically
ike adult organs or bone marrow and elicit strong immune
eactions when transplanted into histocompatibility mismatched
ecipients (15,16). Indeed, the widespread use of autologous cells
s motivated by avoidance of immune rejection. However, har-
esting cells from individual patients poses considerable logistic,
economic and timing constraints, as well as exposure to
potential failures in cell manufacturing and inescapable medical
comorbidities. Allogeneic cardiospheres could circumvent these
limitations and serve as a potential off-the-shelf product in
preventing or reversing post-ischemic left ventricular remodeling
and dysfunction. The rationale for allogeneic cell products is
further strengthened by the emerging realization that long-term
survival of transplanted cells is not a prerequisite for durable
therapeutic benefit (17). Therefore, the objectives of our study
were twofold: first, to characterize the immunologic profile of
cardiospheres and the potential immune responses to transplanted
allogeneic cardiospheres, and second, to compare the effects of
syngeneic and allogeneic cardiospheres on post-ischemic cardiac
structure and function.
Methods
Isolation of secondary cardiospheres. Cardiospheres were
created and expanded as described (7,8). Hearts from male
Wistar Kyoto rats (4 to 6 weeks old; Charles River Labo-
ratories, Reno, Nevada) were processed, and cardiospheres
were formed by replating CDCs in poly-d-lysine-coated
dishes (Invitrogen, Carlsbad, California) to yield “secondary
cardiospheres.” Such secondary cardiospheres have been
shown to be equally effective to primary cardiospheres
formed directly from myocardial outgrowth cells (9). Car-
diospheres, formed from 2 million initially plated CDCs at
passage 1 or 2, were resuspended in 120 l of cold
hosphate-buffered saline (PBS [Invitrogen]) and kept on
ce until injection in each animal (9). For the xenogeneic
roup, secondary cardiospheres were derived from percuta-
eous endomyocardial human heart biopsies, from 5 differ-
nt patients undergoing clinically-indicated procedures after
nformed consent.
low cytometry. Surface alloantigens major histocompati-
ility complex (MHC) I and MHC II and the costimulatory
actors CD80 and CD86 were quantified by flow cytometry
FACS Calibur with CellQuest software, BD Biosciences,
an Jose, California). Singly-passaged CDCs were stained
n parallel and used for gating the cardiospheres according
o object size and optical density. The following polyclonal
onjugated antibodies and isotype matched controls were
sed: MHCI-PE, MHCII-FITC, CD80-APC, and
D86-APC (BD Biosciences).xperimental protocol and animal
urgery. The Wistar Kyoto and
rown Norway rat strains are
ighly inbred and immunologi-
ally divergent (18). Left coro-
ary artery occlusion was per-
ormed in female rats of either
train (6 to 7 weeks old [Charles
iver Laboratories]) under me-
hanical ventilation as described,
ith small modifications (7,19).
riefly, a left thoracotomy and
ericardiotomy were followed by
he induction of a left ventricular
nterior transmural MI by per-
anent ligation of the left ante-
ior descending coronary artery
ith a 7–0 silk suture. The presence
f infarction was verified by pallor at
he apex. Shortly afterwards, cardio-
pheres resuspended as described in
he preceding text were injected in
qually divided doses into 4 peri-
nfarct sites in each animal. For the
ontrol group, 120l PBS was sim-
ilarly injected. Five experimental
groups were used: Wistar Kyoto fe-
male rats plus MI plus cardiospheres
(syngeneic group, n  28), Brown
Norway female rats plus MI plus cardiospheres (allogeneic group,
n  29), Wistar Kyoto female rats plus MI plus PBS (control,
n 27), Brown Norway female plus MI plus PBS (control, n
10), and Brown Norway female plus MI plus human cardio-
spheres (xenogeneic, n  16).
uantitative polymerase chain reaction for cardiosphere
ngraftment. To measure engraftment of injected cardio-
pheres, polymerase chain reaction (PCR) analysis was
erformed from left ventricular tissue 1 week and 3 weeks
fter cell transplantation. Tissue samples (n  5 per group
per time point) were excised and maintained in ribonucleic
acid (RNA) stabilization reagent (Qiagen, Germantown,
Maryland) until processing. The left ventricle was homog-
enized, and total deoxyribonucleic acid (DNA) extracted
using DNAeasy kit (Qiagen). For the standard curve,
genomic DNA extracted from male heart tissue was used.
Quantitative real-time PCR was performed using a Prism
7900 sequence-detection system (Applied Biosystems, Fos-
ter City, California) for 40 total cycles.
Functional evaluation of the left ventricle. Transthoracic
echocardiography was performed with the animals anesthe-
tized by 2% isoflurane. Two-dimensional short- and long-
axis images of the left ventricle were obtained at the
papillary muscle level (Vevo 770, Visual Sonics, Toronto,
Ontario). The following parameters were measured: left
ventricular end-diastolic dimension (LVEDD), left ventric-
Abbreviations
and Acronyms
CDC  cardiosphere-
derived cell
DNA  deoxyribonucleic
acid
HGF  hepatocyte growth
factor
IFN  interferon
IGF  insulin-like growth
factor
IL  interleukin
LV  left ventricular
LVEDD  left ventricular
end-diastolic diameter
LVESD  left ventricular
end-systolic diameter
MHC  major
histocompatibility complex
MI  myocardial infarction
PCR  polymerase chain
reaction
RNA  ribonucleic acid
TNF  tumor necrosis
factor
VEGF  vascular
endothelial growth factorular end-systolic dimension (LVESD), ejection fraction,
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were analyzed, and the average was used for data analysis.
Four different time points were selected for echocardio-
graphic studies: baseline (15 to 18 h after the surgical
procedure), 1 week, 3 weeks, 3 months, and finally, 6
months post-MI.
Tissue collection. For pathology analysis, animals were
uthanized at 1 of 2 time points: 1 week or 3 weeks. Hearts
ere arrested in diastole by intraventricular injection of KCl
10%), excised, embedded in Tissue-Tek OCT compound
Sakura, Torrance, California) and stored at 80°C until
sectioning. Slices 8-m thick taken every 0.2 mm were
tained with hematoxylin and eosin for qualitative assess-
ent of inflammation. Such analysis was performed both in
he peri-infarct zone where the cardiospheres had been
njected, and in the contralateral noninfarcted myocardium
y a cardiac pathologist (D.L.) blinded as to experimental
roup assignment.
nfarct size, morphometry analysis. Scar size was mea-
ured as infarct mass divided by total LV mass as described
20). The left ventricle was weighed and then immersed in
CT compound. Sections from tissue collected 1 week, 3
eeks, and 6 months after cell transplantation were stained
ith Masson’s trichrome. Morphometric evaluation in-
luded quantification of infarct wall thickness and nonin-
arcted remote wall thickness. Six to 10 sections per heart,
rom 5 hearts in each group, were analyzed and averaged.
ollagen content quantification. Tissue sections collected
t 3 weeks were stained with 0.1% picrosirius red (Sigma
ldrich, St. Louis, Missouri) for collagen content evaluation
ithin the infarct zone (21). Ten to 15 images from the
nfarcted region of each heart were obtained with a 40
bjective lens under polarized light microscope. Three
earts per group were included, and images were analyzed
sing Image J software. The collagen content was calculated
s a percentage of the area of each image.
mmunostaining and immunohistochemistry. Secondary
ardiospheres were fixed in a 50% ethanol/50% acetone
olution, blocked, permeabilized, and stained with the
ollowing antibodies for confocal fluorescence imaging:
abbit anti-rat c-kit (Santa Cruz, Santa Cruz, California),
abbit anti-rat CD 105 (Abcam, Cambridge, Massachu-
etts), rabbit anti-rat Cx 43 (Abcam), mouse anti-rat CD 45
Bd Biosciences), PE-conjugated anti-MHCI (Bd Biosci-
nces, San Jose, California), FITC-conjugated anti-MHCII
Bd Biosciences), APC-conjugated anti-CD80 (Bd Biosci-
nces), and APC-conjugated anti-CD86 (Bd Biosciences).
atched isotype controls were used in each case.
For characterization and quantification of the inflamma-
ory cell population in the myocardium, fresh-frozen sec-
ions (8 m) were fixed and stained with the following
rimary antibodies: rabbit anti-rat CD45RA for B mono-
ytes (Serotec), mouse anti-rat CD3 for lymphocytes (Ab-
am), and mouse anti-rat CD 68 for macrophages (Serotec).
pecies-appropriate secondary antibodies were also applied,
ollowed by slide mounting. For each section, cells positive forach antigen were counted in the peri-infarct area in 7 to 10
andom high-power fields and expressed as number per mm2.
ne-way mixed lymphocyte reactions and secreted
ytokines. Lymphocytes isolated from the spleens of each
xperimental group using Ficoll-Hypaque (GE Healthcare,
asadena, California) density gradient centrifugation (22)
ad a viability of 95% assessed by Trypan blue (Invitro-
en) staining. Cardiospheres were pretreated with mitomy-
in C (25 g/ml) to prevent proliferation and added to
lymphocytes pooled from 7 pairs of animal donors at day 7,
and 5 at day 21, in a ratio of 1:10 cardiospheres:lymphocytes
and cocultured for 5 days in the presence of 10% FBS
RPMI 1640 medium (Invitrogen). Lymphocyte prolifera-
tion was determined by BrdU (10 M) incorporation, which
was added for the last 24 h of coculture; optical density was
evaluated with the Amersham Cell proliferation Elisa Biotrak
System (GE Healthcare) according to the manufacturer’s
instructions. Proinflammatory cytokines interferon (IFN)-,
nterleukin (IL)-1, IL-2, IL-6, and tumor necrosis factor
TNF)- were measured in supernatant collected on the fifth
day (with day 7 post-MI lymphocytes) by an array assay (Ray
Biotech, Norcross, Georgia).
Cytokine expression in tissue. The cited cytokines were
also measured (Ray Biotech) in extracts of mildly homoge-
nized peri-infarct tissue (17) at days 1 and 7 post-MI.
Protein concentration was quantified by the BCA kit
(Thermo Scientific, Rockford, Illinois), and a total of 200
g was used in each sample (n  3 in each group). Results
were analyzed by Image J and expressed as optical density
units.
Paracrine effect, growth factors. Tissue expression of
vascular endothelial growth factor (VEGF), hepatocyte
growth factor (HGF), and insulin-like growth factor (IGF)
was evaluated by Western blots at days 1 and 7 post-MI in
both peri-infarct and remote zones. A total of 100 g
protein (n  3 in each group) was processed, and the
following primary antibodies were used: rabbit anti-rat
HGF (Abcam), mouse anti-rat VEGF (Abcam), and mouse
anti-rat IGF (Abcam). Anti-rabbit and anti-mouse horse-
radish peroxidase conjugated secondary antibodies (Cell
Signaling, Danvers, Massachusetts) were used for detection.
ImageJ software was used for quantitation, and each factor’s
expression was normalized by that of -actin.
Statistical analysis. All results are presented as mean 
SD unless specified. Student’s t test was used for compari-
ons between 2 independent groups. Paired data were
ompared using paired t test. Multiple groups were com-
ared using 1-way analysis of variance, and the Bonferroni
est for between-group comparisons. Statistical significance
evel was set at p  0.05. Data were analyzed using Prism
software (version 4.00, GraphPad, San Diego, California).
Although the experimental design included 2 different
control groups (Brown Norway and Wistar Kyoto), there
were no differences between them in any of the parameters
studied. As a result, the 2 control groups were pooled into
a single control group for final analysis.
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Cardiosphere in vitro characteristics. Cardiospheres had
a mean diameter of 47.4 9.75 m, and each contained 54
7 nuclei as assessed by Cellometer (Nexcelom Bioscience,
awrence, Massachusetts). The passage through the 30G
eedle used affected neither their integrity nor their viability
Online Fig. 1). Given the overall cardiosphere-forming cell
umber of 2 106, which was used to quantify dosage as
reviously described (9), approximately 40,000 individual
ardiospheres ended up being injected in each animal.
onsistent with previous findings (9,23), rat cardiospheres
re multicellular microtissues that express c-kit as well as
esenchymal/endothelial cell markers (CD 105), but no
etectable hematopoietic markers (CD 45) (Figs. 1A to
D). Immunologically, cardiospheres created from first- or
econd-passage CDCs comprised a single phenotypic pop-
Figure 1 Characterization of Cardiospheres In Vitro
Immunostaining of selected antigens reveals (A) c-kit preferentially localized in the
absence of CD 45, (E) expression of major histocompatibility complex (MHC) I and
with interferon (IFN)-. (H, I) Flow cytometry plots of the surface antigens MHC I a
DAPI  4’,6-diamidino-2-phenylindole.lation by flow cytometric and immunohistochemical anal-
sis of surface alloantigens (Figs. 1E to 1H). Cardiospheres
nder normal culture conditions expressed intermediate levels of
he major histocompatibility complex I (MHC I 78  2.8%)
n their outer layer, but no detectable MHC II or costimu-
atory molecules CD 80 and CD 86 (Fig. 1E). Similar
esults were observed with human cardiospheres (Online
ig. 2). Only after stimulation with interferon  (100 IU)
ver 7 days was MHC II antigen expressed, reaching 87 
.5% on the last day of treatment (Figs. 1H and 1I).
eft ventricular function. One week after MI, both the
yngeneic and allogeneic groups exhibited increases in
jection fraction and fractional shortening compared to
ontrol (Figs. 2A to 2F and 3A to 3C). The improvement
n LV function was sustained at 3 weeks, 3 months, and 6
onths of follow-up in both syngeneic and allogeneic
r of the cardiosphere, (B) CD 105 and (C) Cx 43 on the outer layer, (D) the
II under normal conditions, and after (F) 3 days or (G) 7 days of stimulation
C II before (Normal CSp) and at various times after stimulation with IFN-.cente
MHC
nd MH
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Allogeneic Cardiospheres After Cardiac Infarction March 12, 2013:1108–19groups (Fig. 2B and 2C). In addition, adverse remodeling
(as manifested by increases in LVEDD and LVESD) was
attenuated in both the syngeneic and allogeneic groups
compared to controls. Interestingly, LVEDD and LVESD
were increased in the control group by 3 weeks but not in
the syngeneic or allogeneic groups (Figs. 2D and 2E). This
attenuation of enlargement in both treated groups contin-
ued up to 6 months (Figs. 2D and 2E).
Engraftment. Consistent with previous observations (9),
Figure 2 Cardiac Function and Cell Engraftment
Left ventricular function and remodeling in controls (vehicle injection), and in groups in
axis echocardiographic images at 6 months from the control, syngeneic, and allogene
muscle shows equivalent improvement in both syngeneic group (green line) and allog
to controls (red line) and to xenogeneic group (black line); the latter was followed up
findings in panel B. (D) Left ventricular end-diastolic diameter (LVEDD) and (E) left ven
syngeneic and allogeneic groups. (F) Percentage engraftment of cardiospheres at 1 w
group (green bars) and allogeneic group (blue bars). All data are mean  SD. *ppercentage engraftment at 1 week was in the single digits.This was the case both for syngeneic and allogeneic hearts
(Fig. 2F). By 3 weeks, 1% transplanted cell survival was
evident in either treated group. In fact, no surviving cells
were detectable in any of the 5 allogeneic hearts examined at
this time. However, there were no statistically significant
differences in engraftment, when comparing syngeneic and
allogeneic hearts. In the xenogeneic group though, no live
cells could be identified even at day 7. Our observation that
no allogeneic CSps survive at 21 days dissociates this measure
with syngeneic, allogeneic, or xenogeneic cardiospheres. (A) Representative long-
ps. (B) Ejection fraction calculated from long-axis views at the level of the papillary
roup (blue line) at 1 week, 3 weeks, 3 months, and 6 months of follow up, relative
ly 3 weeks. (C) Fractional shortening calculated from m-mode scans support the
r end-systolic diameter (LVESD) reveal attenuation of left ventricular remodeling in
nd 3 weeks post-injection reveal minimal to no survival at 3 weeks in syngeneic
5 treated versus control. p  0.05 treated versus xenogeneic.jected
ic grou
eneic g
for on
tricula
eek a
 0.0of engraftment from long-term functional outcomes.
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March 12, 2013:1108–19 Allogeneic Cardiospheres After Cardiac InfarctionChanges in infarct size and left ventricle morphometry. At 1
week or 3 weeks after cell transplantation, scar size was
reduced in both syngeneic and allogeneic groups compared
to the control and xenogeneic groups; the difference was
maintained up to 6 months (Figs. 3A and 3B). In addition,
infarct wall thickness was greater in the syngeneic and
allogeneic cardiosphere-treated groups. Areas of viable
myocardium were regularly evident within the infarct re-
gion, in contrast to the thin, transmural scar tissue that
prevailed in the control and xenogeneic groups (Fig. 3C).
We also quantified thinning ratio, which is defined as the
ratio of the infarct wall thickness to contralateral nonin-
farcted wall thickness (24). Both syngeneic and allogeneic
Figure 3 Infarct Size and Left Ventricular Morphometry
(A) Representative Masson’s trichrome-stained heart tissue cross sections at 1 a
titative analysis of (B) infarct size, 1 week (p  0.01 for both treated groups vs. c
syngeneic [green bars] vs. control), and 6 months (p  0.05 for both treated grou
tum thickness (p  0.01 for both treated groups vs. control); and (E) thinning rati
of control, syngeneic, and allogeneic groups. Images represent stained slides visu
myocardium) and under polarized light (black is the normal myocardium, and oran
ImageJ. Data are mean  SD. *p  0.05 treated versus control. p  0.05 treacardiosphere injections maintained a higher ratio, reflectingrelatively preserved cardiac architecture compared to the
remodeled vehicle-treated group (Figs. 3D and 3E).
Collagen content in the infarct region. Given the reduc-
tions of infarct size with cardiospheres (Fig. 3B), we
looked for a potential antifibrotic effect as part of the
mechanism of action. Three weeks post-MI, collagen
content within the infarct region was higher in the
control group than in either treated group, reflecting the
presence of more viable tissue (Figs. 3F and 3G).
Specifically, the total amount of collagen within the
infarct area was reduced by 15% in the syngeneic and 17%
in the allogeneic group relative to control (Fig. 3G).
These results support the hypothesis that both limitation
eeks. Scar tissue and viable mass appear gray-blue and red, respectively. Quan-
[red bars]), 3 weeks (p  0.01 allogeneic [blue bars] vs. control; p  0.001
control); black bars indicate xenogeneic; (C) infarcted wall thickness; (D) sep-
0.01 for both treated groups vs. control). (F) Sirius red-stained tissue sections
under bright field (red color correlates with collagen, and yellow with normal
the collagen). (G) Quantification of total collagen content in the infarct site by
sus xenogeneic.nd 3 w
ontrol
ps vs.
o (p 
alized
ge-red
ted verof collagen accumulation in the scar, as well as myocyte
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Allogeneic Cardiospheres After Cardiac Infarction March 12, 2013:1108–19regeneration and/or preservation, underlie the functional
improvement due to cardiosphere injection.
Lymphocyte proliferative response. The coculture of car-
diospheres with lymphocytes caused modest lymphocyte
proliferation, which did not differ between syngeneic and
allogeneic groups at 1 week (p  0.096) or 3 weeks (p 
0.7) (Fig. 4A). The stimulation index, defined as the ratio of
allogeneic to syngeneic proliferation (25), was 1.23  0.1 at
1 week and 1.1  0.038 at 3 weeks. Although there seemed
to be a reduction in lymphocyte proliferation from 1 week to
3 weeks, the difference was not significant. In the xenoge-
neic group, which was included as a positive control, the
proliferation ratio ranged from 5.2 0.86 at week 1, to 4
.14 at 3 weeks (Fig. 4A), verifying the sensitivity of the
ixed lymphocyte reaction assay.
eduction of proinflammatory cytokines in the coculture
f syngeneic and allogeneic lymphocytes with cardio-
pheres. As shown in Figure 4B, the proinflammatory
ytokines IFN-, IL-1, IL-2, IL-6, and TNF- remained
at baseline levels when cardiospheres were cocultured with
syngeneic or allogeneic lymphocytes, in contrast to the
xenogeneic group where these cytokines were elevated.
Monocyte infiltration. Hematoxylin and eosin–stained
sections did not reveal signs of immune rejection such as
edema, hemorrhage, or necrosis in either the syngeneic or
allogeneic group. Such was the case in both peri-infarct and
remote areas examined 1 and 3 weeks post-MI (Figs. 4C to
4F). Monocyte infiltration actually tended to be diminished
in both treated groups at day 21. In contrast, robust
cell-mediated rejection (a term adopted for the purposes of
this study according to the International Society of Heart
and Lung Transplantation criteria [26]) was evident in the
xenogeneic group at both time points, with pleomorphic cell
infiltration including numerous lymphocytes. Hemosiderin
accumulation and coagulative necrosis, sequelae of myocar-
dium broken down by local inflammation, were present only
in the xenogeneic group. Quantitative immunohistochemistry 7
days after cardiosphere injection showed that CD 45RA and
macrophage infiltration tended to be lower in both syngeneic
and allogeneic groups compared to control (allogeneic 45 
12, syngeneic 30  10, and control 60  17 for CD 45RA
onocytes; and allogeneic 68 24, syngeneic 60 25, and
ontrol 85  34 cells/mm2 for macrophages), whereas by
ay 21, they decreased in number and could barely be
dentified in the border zone of the infarcted area. Infiltrat-
ng lymphocytes exhibited the same pattern: no difference
etween syngeneic or allogeneic groups and control at day 7,
hen the peak in their proliferation has been reported (27)
Figs. 4E and 4F) (allogeneic 225  55, syngeneic 215 
3, control 187  35 cells/mm2), but a decrease below
ontrol levels at day 21, indicating attenuated chronic
nflammation after MI in syngeneic and allogeneic hearts.
n the xenogeneic group, however, much greater mononu-
lear and polynuclear cell infiltration was present at days 7
nd 21, reflecting cell-mediated rejection and intensified
ocal inflammation (CD 45RA cells 534 12, macrophages08  20, lymphocytes 1,225  35 cells/mm2 ) (Figs. 4E
nd 4F).
educed proinflammatory cytokines in the border
one. Cytokines are among the major triggers of the
nflammatory response after cardiac tissue damage (28). At
ay 1 after cell transplantation, there was no significant
levation of TNF-, IFN-, IL-6, and IL-1 in the
yngeneic or allogeneic groups relative to controls, consis-
ent with the lack of an enhanced inflammatory response
ue to cell injections (p  0.05 for treated vs. control
group) (Fig. 5A). Interestingly, 7 days after treatment,
tissue levels of the same cytokines tended to be reduced in
both treated groups compared to control evaluated by
cytokine array (syngeneic p  0.059, allogeneic p  0.1 vs.
control) (Figs. 5B and 5C). The latter finding may reflect an
immunomodulatory effect of cardiospheres, attenuating the
post-MI inflammatory milieu. Such a conjecture is bolstered
by the reduction of tissue inflammation seen with either
syngeneic or allogeneic cardiosphere injection.
Production of growth factors after cardiosphere injection.
Consistent with the previously described secretion of soluble
growth factors by cardiospheres (9) or CDCs (17), we
identified higher expression of VEGF, IGF, and HGF in
the peri-infarct region in both syngeneic and allogeneic
groups compared to control. More specifically, at day 1,
VEGF and IGF were up-regulated 2-fold, and HGF
threefold, compared to control (p  0.05 for treated vs.
control), whereas at day 7, only HGF remained elevated
(Figs. 6A to 6C). In the xenogeneic group, cytokine expres-
sion was evaluated only at day 1, given the evanescence of
transplanted xenogeneic cardiosphere survival. The modest
elevations in cytokine levels relative to the control group
level did not reach significance. We also evaluated the
expression of the same growth factors in the remote area
(defined here as the septum) (Online Fig. 3). An increase in
the expression of VEGF, HGF, and IGF in this region was
observed in both treated groups at day 1, a finding that
supports the paracrine role of the injected cells and reflects
the better-preserved myocardial structure in this region.
As a structural correlate of the observed changes in
growth factor secretion, allogeneic cardiospheres performed
equally to syngeneic ones with regard to promoting tissue
angiogenesis. Capillary density evaluated by immunohisto-
chemistry 21 days post-MI revealed twice the number of
capillaries positive for von Willebrand factor in the peri-
infarct zone of both syngeneic and allogeneic animals
compared to the control (Figs. 6D and 6E). The changes in
growth factor secretion may reflect, at least partially, the
anti-remodeling effects described earlier and highlight the
significant role of capillary genesis in the salutary effects of
cardiospheres.
Discussion
We find that allogeneic cardiospheres exert beneficial func-
tional effects equal to those of syngeneic ones, without
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(A) Mixed lymphocyte reactions reveal a lack of lymphocyte proliferation in the presence of allogeneic cardiospheres. Black bars indicate xenogeneic; green bars indi-
cate syngeneic; and blue bars indicate allogeneic. Lymphocytes (1  106 responder cells) were stimulated with 105 mytomycin C-treated cardiospheres for 5 days. The
data are expressed as mean  SD of 7 independent experiments at 1 week and 5 experiments at 3 weeks, each performed in triplicate. (B) Proinflammatory cytokines
in the supernatant of the mixed lymphocyte reactions (MLR). The levels of the cytokines secreted in coculture are normalized to the levels secreted by nonstimulated
lymphocytes. (C, D) Confocal immunohistochemistry images of inflammatory cell infiltration at 1 week and 3 weeks, respectively. (E, F) Quantitation of CD3 (lympho-
cytes), CD68 (macrophages), and CD 45RA (B monocytes) 1 week and 3 weeks after cardiosphere injection reveal marked inflammatory reaction in the xenogeneic
hearts but no excess inflammation in syngeneic or allogeneic groups relative to control (red bars); indeed, there is a tendency to less inflammation at 3 weeks in both
syngeneic and allogeneic groups. Data are mean  SEM. *p  0.05 treated versus control. p  0.05 treated versus xenogeneic.
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proved global LV function as early as 7 days after transplan-
tation, and attenuated adverse remodeling; these beneficial
outcomes were maintained for at least 6 months, far beyond
the time when allogeneic cardiospheres had been cleared (by
3 weeks). The sustained benefit, despite the evanescent
survival of transplanted cardiospheres, indicates that 3
weeks suffices to set in motion dynamic and durable mech-
anisms responsible for cardiac regeneration and repair (17),
such as the capillary neoangiogenesis and the attenuation of
collagen accumulation reported for the first time in our
study. Moreover, the initial significant anti-remodeling
effect was further enhanced by day 21, despite the disap-
pearance of the allogeneic cardiospheres by that time,
further supporting the “role model” hypothesis whereby
cardiac-derived cells have been proposed to trigger endog-
enous repair processes (17).
The salutary effect of allogeneic cardiospheres to blunt
adverse ventricular remodeling was accompanied by a 38%
reduction in scar size at day 7, and a 32% thicker infarcted
wall, than in control (Figs. 3A and 3B). Masson’s trichrome
and Sirius red-stained tissue sections revealed layers of
viable mass within the risk area, in contrast to the thin, more
Figure 5 Cytokines in the Peri-Infarct Area
(A, B) Levels of tumor necrosis factor (	
F)-, interleukin (IL)-6, IL-1, and
interferon (IFN)- at 1 day and 7 days after cardiosphere injection reveal sup-
pression of cytokine levels in the syngeneic group (green bars) and allogeneic
group (blue bars) relative to control (red bars). (C) Representative images of
the cytokine array at day 7. Colors of rectangular margins match the labels of
each of the cytokines evaluated in A. Data are expressed as mean  SD.
*p  0.05.densely fibrotic scar of the control group at day 21, indicat-ing less stiffness in this myocardial territory (29). In addi-
tion, the thinning ratio, which indexes both infarct wall
thinning as well as compensatory hypertrophy in remote
myocardium, was higher in both treated groups compared to
control. Thus, cardiospheres lead to enhanced tissue pres-
ervation and regeneration in MI, which subsequently min-
imizes negative remodeling in remote myocardium de-
scribed in the current study. Meanwhile, growth factors are
more plentiful, as are angiogenic factors (30–35), leading to
a twofold increase of angiogenesis in peri-infarct areas by 3
weeks (Fig. 6E).
Although injection of allogeneic cardiospheres might
logically be expected to elicit an immune response, their
immunological phenotype and the histopathological results
demonstrate otherwise. The expression of MHC I on the
outer layer is important because it protects cardiospheres
against the cytotoxic effect of NK cells, while the absence of
MHC II gives them the potential to escape recognition by
alloreactive CD4 lymphocytes (16,36). In addition to being
MHC II negative, cardiospheres did not express the co-
stimulatory molecules CD 80 and CD 86 required for
induction of effector lymphocytes, supporting the hypoim-
munogenic profile of our preformed microtissues.
Previous in vitro studies from our laboratory (10) have
shown that cardiospheres under normal culture conditions,
besides their remarkable expression of stemness factors,
express cytokines including IL-6, IL-7, IL-8, transforming
growth factor-, macrophage colony-stimulating factor,
and the growth factors HGF and VEGF, which are known
to mute local immune reactions (36,37). These cardiosphere-
secreted factors may blunt the T lymphocyte response, leading to
an evasion of alloreactivity.
Consistent with these findings are our in vitro mixed
lymphocyte reaction data. Allogeneic cardiospheres did not
elicit greater proliferation to lymphocytes than syngeneic
cardiospheres either at 1 week or at 3 weeks after injection.
Moreover, the expression of proinflammatory cytokines was
suppressed in both syngeneic and allogeneic lymphocyte
coculture supernatant. Interestingly, a moderate alleviation
of proliferation at 3 weeks was observed, highlighting the
hypoimmunogenic phenotype of cardiospheres, which con-
sequently resulted in an immunomodulatory profile in the
hostile post-infarct environment.
Indeed, we have found a minimal innate and adaptive
alloimmune cellular response after allogeneic transplanta-
tion. Macrophages, which are the first responders of innate
immunity, were present in a similar proportion in the
treated groups and in the control group at day 7, whereas by
day 21, they were barely apparent in cardiosphere-
transplanted myocardium. In addition, infiltrating CD3 T
cells were similar in number in treated and control groups at
day 7, with few cells found on day 21. Although we did not
examine CD 68 infiltration earlier than 7 days, the tissue
cytokine data at day 1 suggest an attenuated inflammatory
response which was further suppressed by day 7. The 4
proinflammatory cytokines examined—TNF-, IFN-, IL-
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within the first few hours of MI, but can be further
increased in larger infarcts and in the chronic remodeling
phase (28,37). Cardiosphere injection led to a hampered
expression of these cytokines 24 h after MI and cell
transplantation.
Another in vivo study from our laboratory (38) addressed
the immune response to allogeneic CDCs in a similar
Figure 6 Paracrine Factors in the Peri-infarct Myocardium
Quantification of angiogenic and pro-survival growth factors (A) vascular endothelia
factor (IGF) reveal enhanced levels in both the syngeneic group (green bars) and t
bars indicate xenogeneic. Data are presented as fold-changes of each factor relat
the graphs. (D) Confocal images of capillaries in the peri-infarct area 3 weeks afte
indicates von Willebrand factor (vWf). (E) Pooled data show increased capillary de
*p  0.05 treated versus control.model. As seen here with cardiospheres, allogeneic CDCselicited no additional inflammatory response relative to
syngeneic cells (38), but the most important immunologic
finding of our study is that allogeneic cardiospheres did not
trigger an additional inflammatory response even when
compared to the vehicle-treated group. Cardiospheres have
superior functional and morphological effects as compared
to CDCs, when both are delivered by direct intramyocardial
injection (9,12), whereas CDCs have been shown to out-
th factor (VEGF), (B) hepatocyte growth factor (HGF), and (C) insulin-like growth
geneic group (blue bars) 1 day and 7 days after cardiosphere injection. Black
control. Representative images from the Western blots at day 1 appear above
iosphere transplantation: blue indicates 4’,6-diamidino-2-phenylindole (DAPI); red
syngeneic and allogeneic groups as compared to control. Data are mean  SD.l grow
he allo
ive to
r card
nsity inperform other stem cell types currently in the clinic (14).
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nomodulatory cytokines (9,17) may contribute to their
enhanced functional benefits and may be valuable even in
the chronic remodeling inflammatory phase, but this con-
jecture needs to be tested further given the different immune
conditions present in the last case (28).
Conclusions
The large functional and morphological benefits of alloge-
neic cardiospheres in acute MI highlight the therapeutic
potential of these cardiac microtissues. Their hypoimmuno-
genic phenotype enables cardiospheres to evade alloimmune
reactions and to modify the proinflammatory milieu created
after MI. A key unanswered question is the relative thera-
peutic value of cardiospheres and CDCs, especially in light
of the significant regenerative potential of the latter in
humans revealed in the CADUCEUS trial (6). Potential
differences between our 2 cell products in terms of efficacy
will have to be weighed against the fact that CDCs can be
readily delivered through the coronary route, whereas car-
diospheres require more cumbersome intramyocardial injec-
tion. More experiments using clinically realistic delivery meth-
ods in large-animal models will be required to determine the
appropriate development pathway for allogeneic cardiospheres
relative to allogeneic CDCs (which are already advancing to
phase 2 in the ALLSTAR (Allogeneic Heart Stem Cells to
Achieve Myocardial Regeneration) (39).
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